Compare Under Armour Inc Class A (UA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? Under Armour Inc Class A trades at $4.78 (market cap $2.07B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 61.6× Under Armour Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Under Armour Inc Class A for 18 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UA | VRTX | |
|---|---|---|
Market Cap | $2.07B | $127.55B |
Volume | 2,680,141 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $557.96 |
52-Week Low | $3.96 | $407.37 |
Typical Hold Time | 18 Days | 120 Days |
Enterprise Value | $3.05B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.74, up 0.85% with a bullish technical signal despite mixed fundamentals. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability margins. Cash flow remains negative with $362M outflow in 2025, while analyst consensus shows divided opinions with 40% buy ratings amid ongoing operational challenges.
Outlook remains challenging with revenue guidance cuts and persistent net losses. Investment opportunity exists in potential turnaround execution, but risks include competitive pressures and weak consumer demand. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations and return to profitability.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
